Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide

Withdrawn before enrolling · Not applicable

Conditions studied: Metastatic Castration Resistant Prostate Cancer (mCRPC)

In brief

This randomized pilot study will be conducted in men with metastatic castration resistant prostate cancer (mCRPC) within 3 months of initiating abiraterone or enzalutamide. The purpose of this pilot study is to evaluate the effects of a 12 week exercise intervention in mCRPC patients who have recently started on additional androgen suppression therapy.

Key facts

Study ID
NCT02130947
Run by
UNC Lineberger Comprehensive Cancer Center
People needed
0
Starts
2014-04-01
Expected to finish
2016-02-01
Last updated by the study team
2016-02-11

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.